Log In
Print
BCIQ
Print
Print this Print this
 

NKTT120

  Manage Alerts
Collapse Summary General Information
Company NKT Therapeutics Inc.
DescriptionHumanized mAb targeting invariant NK T (iNKT) cells
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSickle cell disease
Indication DetailsTreat sickle cell disease
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today